Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. (NY: OGN )

21.00 +0.03 (+0.14%)
Streaming Delayed Price Updated: 3:57 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Organon & Co.

< Previous 1 2 3 4 5 6 Next >
After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022
Upgrades 
Via Benzinga
This Analyst Predicts $396 For Eli Lilly, Plus Raymond James Slashes PT On This Stock By Over 73%
Raymond James cut the price target for PolyPid Ltd. (NASDAQ: PYPD) from $15 to $4. PolyPid shares fell 7.7% to $1.32 in pre-market trading. 
Via Benzinga
Organon Expects Lower EBITDA Margin For FY22, Clocks Mixed Q2 Earnings
Via Benzinga
Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 297 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 238 companies achieved new lows for the year. 
Via Benzinga
This Women Health Stock Gets Analyst Downgrade On 'Approvability Issues, Restructuring'
Via Benzinga
Merck Spinoff Organon Beats Quarterly Views, But Offers Dim Guidance
Organon's sales and earnings fell less than expected, but 2022 sales guidance missed. 
Via Investor's Business Daily
Earnings Scheduled For February 17, 2022
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
A Look Into Healthcare Sector Value Stocks
  Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
Upgrades 
Via Benzinga
Organon: Q2 Earnings Insights
  Organon (NYSE:OGN) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Organon reported in-line EPS of $1.25... 
Via Benzinga
Week In Review: Joincare Plans $300-$400 Million IPO On Swiss Exchange
Joincare Pharmaceutical of Shenzhen plans to list on the SIX Swiss stock exchange, an unusual venue for a China biopharma. The company said it aims to broaden its financing sources and increase global... 
Via Talk Markets
Market Selloff
In a U.S. market selloff, the strong performance of mostly foreign issues was impressive. 
Via Talk Markets
Organon Easily Beats First-Quarter Expectations Despite Nexplanon Slip-Up
The firm's biggest product sustained a hit due to exchange rates and buying patterns. 
Via Investor's Business Daily
Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment
Organon & Co (NYSE: OGN)  
Via Benzinga
Healthy Pharma Favorites
Here's a look at two drug makers that we recommend in our Growth & Income Portfolio. The stocks in this portfolio are generally higher-quality, larger-cap companies that have fallen out of favor. 
Via Talk Markets
AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar
Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-... 
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
World Markets News For Thursday
Ericsson stock lost another 5.27% today in US markets. 
Via Talk Markets
Established Brands Hit Organon's Q4 Sales, Expects FY22 Sales Of Upto $6.4B
Organon & Co's (NYSE: OGN) Q4 FY21 sales decreased 1% to $1.6 billion, beating the consensus of $1.57 billion. Women's Health increased 6%, driven primarily... 
Via Benzinga
Nuclear Winter
Mexico is raising interest rates to 6%, from 5.5%. 
Via Talk Markets
Warren Buffett Is Selling These Stocks
Looking to make money moves like Warren Buffett? Want to know which stocks Buffett is selling? Interested in finding out why these stock sales might be a huge mistake? 
Via Talk Markets
Tuesday Markets Coverage
GE was up on hopes for cheaper oil. But most stocks were down on oil price hike fears. 
Via Talk Markets
Novartis May Have Buyer(s) For Its Sandoz Unit - Report
According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG... 
Via Benzinga
3 Recent Spin-Off Stocks Worth A Spot in Your Portfolio
Spin-off stocks can be lucrative for shareholders in both legacy businesses and recently created public companies. Here are three to know. 
Via InvestorPlace
Berkshire Exited Merck Before COVID Pill Boost; Trimmed Holdings In AbbVie, Bristol Myers In Q3
Warren Buffett's Berkshire Hathaway Inc (NYSE: BRK-A) cleared its stake in Merck & Co Inc (NYSE: MRK) in Q3, right on the eve of a significant stock... 
Via Benzinga
Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
Warren Buffet's Berkshire Hathaway added more than 13 million shares. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.